Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma

The study included : * A screening phase up to 21 days followed by registration * Treatment initiation within 5 working days of registration * A treatment phase with 14-day study treatment cycles until a study withdrawal criterion was met or up to the clinical database cut-off date (18 July 2008) * A follow-up phase - up to 60 days after end of treatment Withdrawal criteria that led to treatment discontinuation were: * The participant or their legally authorized representative requested to withdraw * In the investigator's opinion, continuation of the study would be detrimental to the participant's well being, due to reasons such as disease progression, unacceptable toxicity, noncompliance, or logistical considerations. * A specific request by the Sponsor * Participant had intercurrent illness that prevented further administration of study treatment * Participant had more than 2 aflibercept dose reductions * Participant had arterial thromboembolic events, including cerebrovascular accidents, myocardial infarctions, transient ischemic attacks, new onset or worsening of pre-existing angina * Participant had radiographic evidence of intestinal obstruction (e.g., dilated loops of bowel accompanied by air-fluid levels) or gastrointestinal perforation (e.g., presence of extraluminal gas) requiring surgical intervention * Participant was lost to follow-up After discontinuing treatment, participants remained on the study until the last post-treatment visit or until recovery of drug related toxicities, whichever was later.